Clinical trials
catalyst calendar across sponsors →Studies where BIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 observational · 1 with posted results
Held by 12 tracked-famous managers (First Eagle Investment Management, LLC, ARIEL INVESTMENTS, LLC, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, +7 more) · FINRA short interest 4.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental AssayNCT02401555results2017-03-28observationalDiagnostic Result of Assay (Bio-Rad Geenius HIV 1/2 Supplemental Assay) From Accuracy Analysis | — | Completed | Device: Geenius HIV1/2 Supplemental Assay | HIV | 419 | Dec 2013actual | 2017-03-28 |
| Dengue Virus NS1 Antigen (Bio-Rad) Clinical ProtocolNCT01226173observationalNumber of blood donors with repeatedly reactive Platelia Dengue NS1 Ag test results. | — | Completed | Device: Bio-Rad Platelia Dengue NS1 Ag test | Mass Screening | 182,353 | Aug 2012actual | 2012-09-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19